EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
about
Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKIMolecular interactions in the development of brain metastasesDownregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case reportDNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib.Systematic discovery of complex insertions and deletions in human cancers.Peritoneal and meningeal relapse from lung adenocarcinoma after a response to gefitinib: A case report.EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report.[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].Current chemotherapeutic regimens for brain metastases treatment.Characteristics of patients with brain metastases from lung cancer in a palliative care center.Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.Therapie von Hirnmetastasen und Meningeosis neoplastica
P2860
Q26798043-43880923-B6AE-4AAD-AAD8-7E6E1F29F018Q26865865-FF7F8EC6-4554-4A64-BC09-6F5533251A84Q33597567-ADF02755-87B9-47FD-8942-40D903100F34Q34002791-19D1EB0A-6768-4B50-AE63-511D3CFF340EQ35986801-7628FDDF-9A0D-41CD-ADEA-EC2A8D2612BCQ36168701-EF23DB16-48C7-4C8E-B92D-ECA03BD8C9A3Q37214774-8F104C47-7EA7-42CC-A01A-C9911B4F8BD0Q37560791-372F9681-E9B6-4593-9A42-E03991584F88Q40414834-58F49F7E-604F-4BB8-9571-05F7F29824CDQ41846992-2225D0AF-BCAE-47EB-ADFF-F2CF84AF00FEQ43779640-AE78B6E7-9209-422F-AB25-4A5BDBA20591Q48109517-6442CF2C-4E7B-40C8-AABA-61F8D80FA715Q48278009-92B38513-9C4F-4957-A171-A9BCB9DC4EB6Q52559905-289E29C0-3826-4382-8214-075BE3B521EAQ54356532-A02E886F-1384-4248-AA61-9D61D3CF81C6Q58023833-F818086E-3582-415F-8158-388899ED87B4
P2860
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
@en
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
@nl
type
label
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
@en
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
@nl
prefLabel
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
@en
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
@nl
P2093
P1476
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
@en
P2093
A Neuville
A-C Voegeli
A-M Ruppert
B Mennecier
M Beau-Faller
P304
P356
10.1183/09031936.00162307
P50
P577
2009-02-01T00:00:00Z